Journals / Eurasian Journal of Medicine / 2022 / Cilt: 54 - Sayı: 1

Influence of Lipoxin-A4 Treatment on Cytokine, Chemokine Genes Expression, and Phenotypic Distribution of Lymphocyte Subsets During Experimental Liver Fibrosis

Pages
27–35
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Lipoxin A4 performs its anti-inflammatory effect by reducing the frequency of activated T cells and expression levels of chemokines cytokines responsible from inflammatory immune response in the liver.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Lipoxins are anti-inflammatory, pro-resolving molecules that are secreted by immune cells such as neutrophils and macrophages.
📊
Key Findings & Data:In this study, phenotypic distribution activation markers of lymphocytes in the spleen and expression levels of chemokines (chemokine (C-X-C motif) receptor 3, chemokine (C-X-C motif) ligand 10) cytokines (interferon gamma, tumor necrosis factor alpha, interleukin-6, interleukin-10) in the liver of lipoxin A4-treated fibrotic mice were investigated.
💡
Conclusion & Impact:Conclusion: Lipoxin A4 performs its anti-inflammatory effect by reducing the frequency of activated T cells and expression levels of chemokines cytokines responsible from inflammatory immune response in the liver.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Lipoxins are anti-inflammatory, pro-resolving molecules that are secreted by immune cells such as neutrophils and macrophages. Lipoxins are a metabolite of the arachidonic acid pathway that resolve inflammation in fibrotic liver by producing several anti-inflammatory molecules. In this study, phenotypic distribution activation markers of lymphocytes in the spleen and expression levels of chemokines (chemokine (C-X-C motif) receptor 3, chemokine (C-X-C motif) ligand 10) cytokines (interferon gamma, tumor necrosis factor alpha, interleukin-6, interleukin-10) in the liver of lipoxin A4-treated fibrotic mice were investigated. Materials and methods: Liver fibrosis was induced in BALB/c mice by thioacetamide administration. Lipoxin A4 was administered during last 2 weeks of induction. Fibrosis level was determined by using Knodell scoring. Lymphocytes were identified by flow-cytometry. Expression levels of genes were measured by quantitative real time polymerase chain reaction in liver homogenates. Results: Lipoxin A4 treatment caused an elevation of T-lymphocyte percentage in the spleen. Interestingly, administration of lipoxin A4 significantly reduced B-lymphocyte population in spleen of fibrotic group. CD8+ cytotoxic T cell frequency significantly reduced in thioacetamide-induced mice; however, lipoxin A4 administration increased that percentage significantly. Lipoxin A4 treatment significantly reduced frequency of activated ($CD8^+$$CD69^+$) cytotoxic T cells. Expression levels of chemokines significantly reduced in the liver after lipoxin A4 treatment. While expression levels of interferon gamma, tumor necrosis factor alpha, and interleukin-6 significantly reduced in the liver after lipoxin A4 treatment, an anti-inflammatory cytokine interleukin-10 expression was almost at similar levels in all experimental groups. Conclusion: Lipoxin A4 performs its anti-inflammatory effect by reducing the frequency of activated T cells and expression levels of chemokines cytokines responsible from inflammatory immune response in the liver.

🔖

Cite This Article

GÜL, M., KAYHAN, B., KARACA, Z. M., KURTOĞLU, E. L. (2022). Influence of Lipoxin-A4 Treatment on Cytokine, Chemokine Genes Expression, and Phenotypic Distribution of Lymphocyte Subsets During Experimental Liver Fibrosis. Eurasian Journal of Medicine, Cilt: 54 - Sayı: 1, 27–35. https://ajindex.com/articles/508778

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanism of progression and resolution. Clin Sci (Lond). 2007
  2. 112(5):265-280. [CrossRef] 2. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol. 2007
  3. 22(suppl 1):S79-S84. [CrossRef] 3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005
  4. 115(2):209-218. [CrossRef] 4. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007
  5. 22(5):634-638. [CrossRef] 5. Yamaguchi N, Mezaki Y, Miura M, et al. Antiproliferative and proapoptotic effects of tocopherol and tocol on activated hepatic stellate cells. J Nutr Sci Vitaminol (Tokyo). 2011
  6. 57(5):317-325. [CrossRef] 6. Ahmad A, Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol. 2012
  7. 18(3):155- 167. [CrossRef] 7. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006
  8. 6(4):414-420. [CrossRef] 8. Serhan CN, Fahlstadius P, Dahlén SE, Hamberg M, Samuelsson B. Biosynthesis and biological activities of lipoxins. Adv Prostaglandin Thromboxane Leukot Res. 1985
  9. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005
  10. 6(12):1191-1197. [CrossRef] 10. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8 and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol. 2000
  11. 164(5):2660-2666. [CrossRef] 11. Gewirtz AT, McCormick B, Neish AS, et al. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. J Clin Invest. 1998
  12. 101(9):1860-1869. [CrossRef] 12. Kurtoğlu EL, Kayhan B, Gül M, et al. A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes. Turk J Gastroenterol. 2019
  13. 30(8):745-757. [CrossRef] 13. Kurtoğlu EL. Karaciğer Fibrozunun Tedavisinde Lipoksin A4 Kullanımı. İ.Ü. Sağlık Bilimleri Enstitsü Doktora Tezi. 2016. 14. Xu Z, Zhao F, Lin F, Chen J, Huang Y. Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and antiangiogenesis. Am J Reprod